Dermacyte Oxygenating Eye Complex is a lightweight, paraben-free oxygen-carrying serum bolstered by restorative ingredients such as Vitamin C, soothing oat kernel, antioxidants, hydrating sunflower oil and avocado essence. Furthermore, seed extracts from the Pacific and Northeast Meadowfoam plant aid in water loss prevention, a vital component to help overcome the drying effects of winter.
Oxycyte is a sterile, milky white, sub-micron (median diameter of 200-250 nm) perfluorocarbon (PFC) emulsion intended for intravenous injection. It contains two key ingredients, perfluoro(t-butylcyclohexane) and egg yolk phospholipids (an emulsifier), along with several minor ingredients dispersed in water. Research has shown that PFCs can dissolve and release large amounts of gases, including oxygen and carbon dioxide. When formulated and delivered as an intravenous emulsion, PFCs have been shown to enhance the oxygenation of ischemic tissue.
About Oxygen Biotherapeutics, Inc.Oxygen Biotherapeutics, Inc. is developing medical products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte ® that is currently in clinical and preclinical studies for intravenous delivery for indications such as traumatic brain injury, decompression sickness and stroke. The company has also developed PFC-based creams and gels for topical delivery to the skin potentially for wound care and dermatologic conditions. In addition, the Company has commercialized its Dermacyte ® line of skin care cosmetics for the anti-aging market which, as noted above, has been sublicensed to Valor, SA, Cosmetics Division. Caution Regarding Forward-Looking Statements This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the company’s judgment as of the date of this release. The forward-looking statements are subject to a number of risks and uncertainties including matters beyond the company’s control that could lead to delays in the commercialization of Dermacyte by Valor, our clinical study, new product introductions and customer acceptance of these new products, and other risks and uncertainties as described in our filings with the Securities and Exchange Commission, including in the current Form 10-Q filed on December 14, 2012, and our annual report on Form 10-K filed on July 24, 2012, as well as other filings with the SEC. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.